P&T
Our
Other
Journal
MediMedia Managed Markets
Managed Care

 

Cost-Sharing Effects on Adherence and Persistence For Second-Generation Antipsychotics In Commercially Insured Patients

MANAGED CARE August 2010. © MediMedia USA
Peer-Reviewed

Cost-Sharing Effects on Adherence and Persistence For Second-Generation Antipsychotics In Commercially Insured Patients

Teresa B. Gibson, PhD
Thompson Reuters (Healthcare) Inc.
Yonghua Jing, PhD
Bristol-Myers Squibb
Edward Kim, MD, MBA
Eisai Inc. (formerly Bristol-Myers Squibb)
Erin Bagalman, MSW
Thomson Reuters (Healthcare) Inc.
Sara Wang, PhD
Thomson Reuters (Healthcare) Inc.
MANAGED CARE August 2010. ©MediMedia USA

Teresa B. Gibson, PhD

Thompson Reuters (Healthcare) Inc.

Yonghua Jing, PhD

Bristol-Myers Squibb

Edward Kim, MD, MBA

Eisai Inc. (formerly Bristol-Myers Squibb)

Erin Bagalman, MSW

Thomson Reuters (Healthcare) Inc.

Sara Wang, PhD

Thomson Reuters (Healthcare) Inc.

Richard Whitehead

(formerly of Otsuka America Pharmaceutical Inc.)

Quynh-Van Tran, PharmD

Otsuka America Pharmaceutical Inc.

Jalpa A. Doshi, PhD

University of Pennsylvania School of Medicine

ABSTRACT

Purpose: To assess the relationship between patient cost-sharing (e.g., copayments or coinsurance) and adherence and persistence to second-generation (atypical) antipsychotic (SGA) medications.

Design and methodology: A retrospective, observational study of adults aged 18–64 years with schizophrenia or bipolar disorder (n=7,910) who initiated SGA medications with employer-sponsored insurance in the 2003–2006 MarketScan Commercial Claims and Encounters Database.

Adherence was defined as percent of days covered in each calendar quarter. Persistence was defined as days from initiation of SGA to the first 90-day gap in medication on-hand.

Generalized Estimating Equations were used to determine the effects of cost-sharing on adherence to SGA medications based on patient-quarter data.

A Cox proportional hazards model with patient cost-sharing as a time-varying covariate estimated the effects on persistence with SGA medication.

Principal findings: Higher cost-sharing was associated with a lower likelihood of adherence. When compared to plans with cost-sharing below $10, adherence rates were approximately 27% lower for patients in plans with SGA cost-sharing of $50 and above and about 10% lower for patients in plans with cost-sharing between $30 and $50. In both cases, the reduction in adherence was significant. Higher cost-sharing was also associated with a shorter time to discontinuation (HR: 1.028; 95% CI [1.006–1.051]).

Conclusion: High SGA cost-sharing appears to be a financial barrier to SGA medication compliance, especially when cost-sharing levels exceeded $30.

Our findings have implications for health plans, employers, and policymakers who have, or are, contemplating establishing cost-sharing tiers for SGA medications for commercially insured patients with serious mental illnesses.

Meetings

Pharmaceutical Pricing and Contracting Conference Philadelphia, PA September 22–23, 2014
Private Health Insurance Exchanges Conference Washington, D.C. October 7–8, 2014
National Healthcare Facility Management Summit Palm Beach, FL October 16–17, 2014
National Healthcare CFO Summit Las Vegas, NV October 19–21, 2014
National Healthcare CXO Summit Las Vegas, NV October 19–21, 2014
Innovative Member Engagement Operations For Health Plans Las Vegas, NV October 20–21, 2014
4th Partnering With ACOs Summit Los Angeles, CA October 27–28, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014